Total Payments
$219,504
2024 Payments
$31,998
Companies
30
Transactions
518
Medicare Patients
1,372
Medicare Billing
$899,804
Payment Breakdown by Category
Consulting$89,399 (40.7%)
Other$64,574 (29.4%)
Research$29,209 (13.3%)
Travel$21,101 (9.6%)
Food & Beverage$15,167 (6.9%)
Education$54.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,399 | 48 | 40.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $61,194 | 17 | 27.9% |
| Unspecified | $29,209 | 33 | 13.3% |
| Travel and Lodging | $21,101 | 87 | 9.6% |
| Food and Beverage | $15,167 | 325 | 6.9% |
| Honoraria | $3,380 | 2 | 1.5% |
| Education | $54.00 | 6 | 0.0% |
Payments by Type
General
$190,295
485 transactions
Research
$29,209
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $80,195 | 131 | $0 (2024) |
| ABBVIE INC. | $39,833 | 103 | $0 (2024) |
| Allergan, Inc. | $33,688 | 71 | $0 (2021) |
| PFIZER INC. | $17,164 | 27 | $0 (2024) |
| Amgen Inc. | $11,154 | 22 | $0 (2022) |
| Eli Lilly and Company | $6,512 | 18 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $6,147 | 24 | $0 (2020) |
| Axsome Therapeutics, Inc. | $4,375 | 1 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,246 | 13 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $3,696 | 11 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,998 | 56 | PFIZER INC. ($16,731) |
| 2023 | $57,687 | 106 | Lilly USA, LLC ($41,057) |
| 2022 | $50,930 | 87 | ABBVIE INC. ($21,518) |
| 2021 | $16,525 | 41 | Biohaven Pharmaceuticals, Inc. ($3,696) |
| 2020 | $10,608 | 21 | Lilly USA, LLC ($5,436) |
| 2019 | $16,016 | 107 | Lilly USA, LLC ($6,383) |
| 2018 | $20,490 | 66 | Allergan Inc. ($11,708) |
| 2017 | $15,251 | 34 | Allergan Inc. ($14,231) |
All Payment Transactions
518 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $671.90 | General |
| 12/13/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $516.73 | General |
| 12/13/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $478.08 | General |
| 12/13/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $351.90 | General |
| 12/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| 11/16/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $147.59 | General |
| Category: NEUROLOGY | ||||||
| 11/16/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $51.99 | General |
| Category: NEUROLOGY | ||||||
| 11/13/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: NEUROLOGY | ||||||
| 11/07/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Neuroscience | ||||||
| 10/31/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $30.79 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/12/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: Central Nervous System | ||||||
| 09/20/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: PAIN | ||||||
| 09/12/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Neuroscience | ||||||
| 09/05/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $179.84 | General |
| Category: PAIN MANAGEMENT | ||||||
| 09/05/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: PAIN MANAGEMENT | ||||||
| 09/03/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $247.96 | General |
| Category: NEUROLOGY | ||||||
| 09/03/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: NEUROLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: NEUROSCIENCE | ||||||
| 07/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.54 | General |
| Category: NEUROLOGY | ||||||
| 07/09/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,002.00 | General |
| 06/15/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $147.58 | General |
| Category: NEUROLOGY | ||||||
| 06/13/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $44.88 | General |
| Category: NEUROLOGY | ||||||
| 06/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $39.38 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $6,010 | 9 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $4,075 | 4 |
| A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | ABBVIE INC. | $3,100 | 3 |
| A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | AbbVie Inc. | $2,500 | 4 |
| A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | ABBVIE INC. | $2,350 | 3 |
| A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | AbbVie Inc. | $2,200 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH AIMOVIG RESEARCH | Novartis Pharmaceuticals Corporation | $2,019 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $1,905 | 3 |
| A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine | AbbVie Inc. | $1,800 | 1 |
| A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE) | AbbVie Inc. | $1,200 | 1 |
| Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | AbbVie Inc. | $1,200 | 1 |
| Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. | ABBVIE INC. | $850.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 335 | 42,961 | $900,424 | $266,034 |
| 2022 | 11 | 373 | 29,981 | $710,958 | $197,254 |
| 2021 | 10 | 343 | 40,706 | $919,450 | $258,568 |
| 2020 | 9 | 321 | 26,536 | $624,383 | $177,949 |
Total Patients
1,372
Total Services
140,184
Medicare Billing
$899,804
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 68 | 42,435 | $674,640 | $206,551 | 30.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 68 | 216 | $95,040 | $29,000 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 175 | $71,028 | $18,715 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 27 | $16,487 | $4,056 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $14,103 | $2,867 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 30 | $8,604 | $2,103 | 24.4% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2023 | 17 | 31 | $9,988 | $1,742 | 17.4% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 17 | 31 | $10,534 | $1,000 | 9.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 66 | 29,400 | $464,000 | $137,788 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 187 | $73,654 | $20,311 | 27.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 66 | 146 | $64,240 | $19,943 | 31.0% |
| 64400 | Injection of anesthetic agent and/or steroid into face nerve | Office | 2022 | 14 | 72 | $38,906 | $6,277 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 19 | $11,421 | $2,878 | 25.2% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2022 | 24 | 45 | $16,348 | $2,491 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 23 | $5,895 | $1,638 | 27.8% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2022 | 25 | 46 | $17,776 | $1,637 | 9.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $7,756 | $1,606 | 20.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 16 | $7,154 | $1,592 | 22.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 16 | $3,808 | $1,094 | 28.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 62 | 40,001 | $617,600 | $183,855 | 29.8% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 62 | 205 | $90,200 | $27,904 | 30.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 90 | 197 | $70,725 | $22,011 | 31.1% |
| 64400 | Injection of anesthetic agent and/or steroid into trigeminal nerve of face | Office | 2021 | 17 | 115 | $68,610 | $11,394 | 16.6% |
| 64450 | Injection of anesthetic agent and/or steroid into other peripheral nerve or branch | Office | 2021 | 21 | 51 | $21,292 | $3,035 | 14.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 18 | $10,909 | $2,632 | 24.1% |
About Dr. Paul Mathew, M.D
Dr. Paul Mathew, M.D is a Neurology healthcare provider based in Cambridge, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1245495050.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Mathew, M.D has received a total of $219,504 in payments from pharmaceutical and medical device companies, with $31,998 received in 2024. These payments were reported across 518 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($89,399).
As a Medicare-enrolled provider, Mathew has provided services to 1,372 Medicare beneficiaries, totaling 140,184 services with total Medicare billing of $899,804. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Cambridge, MA
- Active Since 07/21/2008
- Last Updated 04/17/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1245495050
Products in Payments
- QULIPTA (Drug) $24,098
- NURTEC ODT (Drug) $14,231
- UBRELVY (Drug) $13,658
- EMGALITY (Drug) $13,505
- BOTOX (Biological) $10,411
- BOTOX - MIGRAINE (Drug) $10,165
- Aimovig (Biological) $9,037
- TROKENDI XR (Drug) $6,147
- ZEMBRACE SYMTOUCH (Drug) $3,314
- TOSYMRA (Drug) $2,844
- AIMOVIG (Biological) $2,450
- BOTOX (Drug) $1,987
- Zembrace (Drug) $902.34
- BOTOX THERAPEUTIC (Biological) $589.60
- VYEPTI (Biological) $575.14
- AJOVY (Biological) $438.20
- QUTENZA (Drug) $315.39
- BOTOX CHRONIC MIGRAINE (Drug) $310.67
- BOTOX - NEUROLOGY (Drug) $249.60
- AJOVY (Drug) $246.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Cambridge
Dr. Priyantha Herath, Md Phd, MD PHD
Neurology — Payments: $23,561
Neurology $23,561
Dr. Oscar Soto, Md, MD
Neurology — Payments: $13,289
Neurology $13,289
Dr. Tony Ho, M.d, M.D
Neurology — Payments: $6,655
Neurology $6,655
Cynthia Carter, Md, MD
Neurology — Payments: $3,418
Neurology $3,418
Nancy Ann Simonian, M.d, M.D
Neurology — Payments: $155.80
Neurology $155.80
Dr. Michael Arena, Md, MD
Neurology — Payments: $124.33
Neurology $124.33